MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

SpringWorks Therapeutics Inc

Fermé

SecteurSoins de santé

46.51 11.53

Résumé

Variation du prix de l'action

24h

Actuel

Min

41.08

Max

46.89

Chiffres clés

By Trading Economics

Revenu

-24M

-77M

Ventes

12M

62M

BPA

-1.04

Marge bénéficiaire

-125.586

Employés

368

EBITDA

-23M

-80M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+71.23% upside

Dividendes

By Dow Jones

Prochains Résultats

1 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-839M

3.3B

Ouverture précédente

34.98

Clôture précédente

46.51

Sentiment de l'Actualité

By Acuity

50%

50%

180 / 386 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

SpringWorks Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

11 févr. 2025, 07:03 UTC

Acquisitions, Fusions, Rachats

Germany's Merck in Talks to Buy SpringWorks Therapeutics

10 févr. 2025, 16:38 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

SpringWorks Therapeutics Shares Rise on Report it May be Acquired

11 févr. 2025, 10:54 UTC

Market Talk
Acquisitions, Fusions, Rachats

Germany's Merck Potential Buy of SpringWorks Therapeutics Puts Its Strategy Into Question -- Market Talk

11 févr. 2025, 10:52 UTC

Market Talk
Acquisitions, Fusions, Rachats

German Merck's Potential Buy of SpringWorks Therapeutics Holds Profitability Risk -- Market Talk

Comparaison

Variation de prix

SpringWorks Therapeutics Inc prévision

Objectif de Prix

By TipRanks

71.23% hausse

Prévisions sur 12 Mois

Moyen 71.71 USD  71.23%

Haut 87 USD

Bas 63 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

7 ratings

7

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

44.13 / 47.505Support & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

180 / 386Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos SpringWorks Therapeutics Inc

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.